Ironwood Pharmaceuticals (IRWD) Share-based Compensation (2010 - 2026)

Ironwood Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $3.7 million in Q1 2026.

• Quarterly Share-based Compensation rose 60783.33% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 44.58% YoY) and the FY2025 annual result came in at $17.2 million, down 42.21% from the prior year.
• Share-based Compensation slipped to $3.7 million in Q1 2026 per IRWD's latest filing, from $3.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $10.1 million in Q1 2024 and troughed at -$19.3 million in Q4 2023.
• A 5-year average of $1.7 million and a median of $1.5 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 364.66% in 2023, then surged 63969.23% in 2024.
• Over 5 years, Share-based Compensation stood at $7.3 million in 2022, then slumped by 364.66% to -$19.3 million in 2023, then soared by 123.66% to $4.6 million in 2024, then retreated by 16.27% to $3.8 million in 2025, then declined by 4.45% to $3.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $3.7 million, $3.8 million, and $1000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.